Generating PDOX Mouse Model of Colorectal Cancer: Studying Progression of Colorectal Cancer in a Murine Model

Executive Industry Relevance

Patient-derived orthotopic xenograft (PDOX) mouse models of colorectal cancer provide a translationally relevant system for studying tumor progression and metastatic patterns in vivo. This approach enables mechanistic de-risking of tumor-stroma interactions and supports predictive confidence in preclinical oncology pipelines. The model's ability to recapitulate human tumor biology informs early discovery, target validation, and risk-adjusted portfolio decisions.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of tumor-stroma interactions, specifically the role of follicular dendritic cells (FDCs) in cancer progression.
• Supports functional target validation by modeling human tumor growth and metastasis in a murine system.
• Facilitates predictive confidence in candidate targets by providing in vivo evidence of biological relevance.

Screening & Assay Development

• Establishes a validated in vivo platform for evaluating tumor growth and metastatic potential of colorectal cancer cells.
• Enables quantitative assessment of tumor burden using bioluminescent imaging for reproducible readouts.
• Supports assay standardization and scalability for compound or intervention screening in a disease-relevant context.

Translational & Preclinical Research

• Provides a disease-relevant preclinical model for studying metastatic dissemination to organs such as lungs and liver.
• Aligns with translational biomarker strategies by enabling longitudinal monitoring of tumor progression.
• Supports continuity from discovery through preclinical validation by modeling patient-derived tumor behavior.

Pipeline & Workflow Integration

The PDOX model integrates into the oncology discovery continuum from early mechanistic studies to preclinical validation of therapeutic hypotheses.

• Discovery Biology: Models the impact of stromal cell interactions on tumor growth and metastasis, supporting hypothesis testing and biological de-risking.
• Screening: Provides a reproducible in vivo assay for evaluating tumor progression and intervention efficacy.
• Analytics: Delivers quantitative bioluminescent imaging outputs for comparative analysis of tumor burden and metastatic spread.
• Translational Research: Bridges discovery and preclinical phases by recapitulating human tumor biology in a murine host.
• Enterprise Reuse: Offers a reusable platform for diverse oncology programs requiring patient-derived, disease-relevant models.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence and target validation by modeling human tumor-stroma interactions in vivo.
• Operational Value: Standardizes in vivo workflows and enables reproducible, quantitative tumor monitoring.
• Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk through mechanistic de-risking.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets based on translationally relevant data.

Implementation Considerations

• Requires expertise in murine surgical techniques and orthotopic implantation procedures.
• Demands access to bioluminescent imaging infrastructure for longitudinal tumor monitoring.
• Necessitates cross-team standardization of cell preparation, injection, and imaging protocols.
• May require adaptation for different tumor histotypes or stromal cell populations.
• Practical limitations include immunocompromised host requirements and model-specific technical challenges.

Biopharma FAQs